reports
Lexicon Pharmaceuticals Presents Additional Pilavapadin Data in Diabet...
Lexicon Pharmaceuticals Presents Additional Pilavapadin Data in Diabetic Peripheral Neuropathic Pain at 19th Annual Pain Therapeutics Summit – Results support advancement of 10 mg dose into Phase 3 development – – End-of-Phase 2 meeting request accepted by U.S. FDA; partnership discussions progressing – THE WOODLANDS, Texas, Oct. 14, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: LXRX) today announced the Company presented additional clinical data and program updates from its Phase 2 pilavapadin program at the 19th Annual Pain Therapeutics Summit. These data follow the from the Phase 2b PROGRESS ...
Lexicon Pharmaceuticals Convenes Roundtable to Address Public Policy G...
Lexicon Pharmaceuticals Convenes Roundtable to Address Public Policy Gaps for People with Chronic Pain Diverse group of stakeholders aligned around the importance of elevating public awareness of need for new treatments for chronic pain and the need to expand the Alternatives to PAIN Act THE WOODLANDS, Texas, Oct. 08, 2025 (GLOBE NEWSWIRE) -- Yesterday, (Nasdaq: LXRX) hosted and participated in a roundtable discussion with experts to explore how to enhance current and future legislative and policy efforts to better meet the needs of Americans suffering from chronic pain. The perspectiv...
SiriusPoint Announces Sale of Arcadian MGA for $139m with Long Term Ca...
SiriusPoint Announces Sale of Arcadian MGA for $139m with Long Term Capacity Deal Until 2031 HAMILTON, Bermuda, Oct. 06, 2025 (GLOBE NEWSWIRE) -- SiriusPoint Ltd. (“SiriusPoint”) (NYSE: SPNT), a global specialty insurer and reinsurer, has today announced its agreement to sell its 49% equity stake in managing general agent, Arcadian Risk Capital (“Arcadian”) to Lee Equity Partners for total consideration of $139 million, inclusive of a pre-close dividend. SiriusPoint has also renewed and extended its capacity agreement with Arcadian until the end of 2031. Upon completion of the sale, Siri...
S&P Global Ratings Revises SiriusPoint’s Outlook to Positive Based on ...
S&P Global Ratings Revises SiriusPoint’s Outlook to Positive Based on Significant Underwriting Profits and Reduced Risk Profile HAMILTON, Bermuda, Oct. 02, 2025 (GLOBE NEWSWIRE) -- S&P Global Ratings (“S&P”) has revised its outlook on SiriusPoint Ltd. (“SiriusPoint”) (NYSE: SPNT) and its operating subsidiaries to Positive from Stable, citing the Company’s underwriting profits over the past two and a half years, and its significantly reduced risk profile. S&P has also affirmed SiriusPoint’s 'A-' issuer credit and financial strength ratings on all core operating subsidiaries, and its 'BBB'...
SiriusPoint Announces Sale of ArmadaCare MGA for $250m with Long Term ...
SiriusPoint Announces Sale of ArmadaCare MGA for $250m with Long Term Capacity Deal Until 2030 HAMILTON, Bermuda, Sept. 29, 2025 (GLOBE NEWSWIRE) -- SiriusPoint Ltd. (“SiriusPoint”) (NYSE: SPNT), a global specialty insurer and reinsurer, has today announced its agreement to sell wholly owned supplemental health insurance program manager, ArmadaCare (“Armada”) to Ambac Financial Group Inc. (“Ambac”) for $250 million. SiriusPoint will continue its capacity partnership with Armada until the end of 2030. Upon completion of the sale, SiriusPoint will recognize a pre-tax gain of $220-230 milli...
Lexicon Pharmaceuticals Announces Update on Submission of Additional D...
Lexicon Pharmaceuticals Announces Update on Submission of Additional Data to U.S. FDA Supporting the Benefit-Risk Profile of Zynquista® in Type 1 Diabetes Data obtained from ongoing third-party funded, investigator-sponsored trials have been submitted in effort to address the December 2024 complete response letter Company seeks alignment on reasonable path forward for Zynquista NDA resubmission FDA feedback from Type D meeting now expected during the fourth quarter THE WOODLANDS, Texas, Sept. 22, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: LXRX) today announced an update to the previous s...
Pilavapadin Provides Meaningful Pain Reduction in Adults with Diabetic...
Pilavapadin Provides Meaningful Pain Reduction in Adults with Diabetic Peripheral Neuropathic Pain (DPNP) in Data Presented at the European Association for the Study of Diabetes (EASD) and NEUROdiab Annual Meetings Pilavapadin 10 mg resulted in a two-point reduction from baseline in average daily pain scores (ADPS) by week 11 and was well tolerated in PROGRESS Phase 2b study THE WOODLANDS, Texas, Sept. 17, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: LXRX) today announced the presentation of clinical data from the company’s Phase 2b PROGRESS study for its investigational, AAK1-inhibitor, pilavapa...
Lexicon Pharmaceuticals to Present Additional Clinical Data on Pilavap...
Lexicon Pharmaceuticals to Present Additional Clinical Data on Pilavapadin at Three Upcoming Medical Meetings Presentations collectively highlight pilavapadin’s potential to improve pain management care for patients with diabetic peripheral neuropathic pain (DPNP) Breadth of the data across Phase 2 program to be discussed at Arrowhead’s 19th Annual Pain Summit THE WOODLANDS, Texas, Sept. 11, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: LXRX) today announced the presentation of clinical data for its investigational, AAK1-inhibitor, pilavapadin, for the treatment of diabetic peripheral neuropathic ...
Lexicon Pharmaceuticals Announces Submission of Additional Data to U.S...
Lexicon Pharmaceuticals Announces Submission of Additional Data to U.S. FDA Supporting the Benefit-Risk Profile of Zynquista® in Type 1 Diabetes Data obtained from ongoing third-party funded, investigator-sponsored trials have been submitted in effort to address the December 2024 complete response letter Company seeks alignment on reasonable path forward for Zynquista NDA resubmission FDA feedback from Type D meeting expected by end of September THE WOODLANDS, Texas, Sept. 08, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: LXRX) today announced that the Company has submitted additional clini...
- Jonathan Moreland
Lexicon Pharmaceuticals to Present New Preclinical Data on Pilavapadin...
Lexicon Pharmaceuticals to Present New Preclinical Data on Pilavapadin in Chemotherapy-Induced Pain and Multiple Sclerosis Pain at NeuPSIG 2025 THE WOODLANDS, Texas, Sept. 04, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: LXRX) today announced that the Company will present new data demonstrating the reduction of neuropathic pain by pilavapadin in preclinical models of chemotherapy-induced peripheral neuropathy (CIPN) and multiple sclerosis (MS) at the 9th International Congress on Neuropathic Pain - (NeuPSIG) 2025. The findings highlight the relevance of inhibiting pilavapadin’s novel target, AAK1, ...
SiriusPoint appoints Martin Hudson to Board of Directors
SiriusPoint appoints Martin Hudson to Board of Directors HAMILTON, Bermuda, Sept. 03, 2025 (GLOBE NEWSWIRE) -- SiriusPoint Ltd. (“SiriusPoint” or the “Company”) (NYSE: SPNT), a global specialty insurer and reinsurer, has today announced the appointment of Martin Hudson as Board Director, effective September 1, 2025. Mr. Hudson has more than 40 years of international (re)insurance leadership experience, spanning underwriting, risk management, governance, and executive management. Since 2015, he has served as an Independent Non-Executive Director and Chair of the Board across a number of c...
Lexicon Pharmaceuticals Announces Presentation of Diabetic Peripheral ...
Lexicon Pharmaceuticals Announces Presentation of Diabetic Peripheral Neuropathic Pain Patient Insights at PAINWeek 2025 THE WOODLANDS, Texas, Sept. 03, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: LXRX) today announced data from a study of patients describing the physical and psychological impact of diabetic peripheral neuropathic pain (DPNP), despite treatment with available over-the-counter and prescription pain relievers will be presented at PAINWeek 2025. The conference is being held September 2-4, 2025, at The Cosmopolitan in Las Vegas, Nevada. Presentation details: Poster #53: ...
Sotagliflozin Provides Consistent Relative Risk Reduction in Heart Fai...
Sotagliflozin Provides Consistent Relative Risk Reduction in Heart Failure and Major Cardiovascular Events Across All Age Ranges, Including Greater Than 75, in Data Presented at the European Society of Cardiology (ESC) 2025 Congress Oral presentation highlighted improvements in heart failure endpoints and major adverse cardiovascular events (MACE) among older adults irrespective of age THE WOODLANDS, Texas, Sept. 02, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: LXRX) announced that a post-hoc analysis (“Efficacy of Sotagliflozin Among Older Adults: A Pooled Analysis of SCORED and SOLOIST-WHF”) of...
Lexicon Pharmaceuticals to Participate at Two Upcoming Investor Confer...
Lexicon Pharmaceuticals to Participate at Two Upcoming Investor Conferences THE WOODLANDS, Texas, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will participate in a fireside chat at Citi's Biopharma Back to School Conference on Wednesday, September 3 at 1:45 p.m. ET and at the H.C. Wainwright 27th Annual Global Investment Conference on Monday, September 8 at 3:00 p.m. ET. The live events and replays of the presentations can be accessed via the Events page of the Company’s website at . About Lexicon Pharmaceuticals...
Lexicon Pharmaceuticals Reports Second Quarter 2025 Financial Results ...
Lexicon Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Updates Partnership discussions for pilavapadin remain underway following Phase 2b PROGRESS study results IND-enabling studies of LX9851 for obesity and related disorders on track for completion in 2025 with licensee Novo Nordisk expected to submit IND Enrollment completion for SONATA Phase 3 study in both obstructive and non-obstructive hypertrophic cardiomyopathy (HCM) on target for 2026 Conference call and webcast at 8:30 am ET THE WOODLANDS, Texas, Aug. 06, 2025 (GLOBE NEWSWIRE) -- (Na...
SiriusPoint Reports Second Quarter 2025 Results with Improvement in Co...
SiriusPoint Reports Second Quarter 2025 Results with Improvement in Core Combined Ratio to 89.5% HAMILTON, Bermuda, Aug. 04, 2025 (GLOBE NEWSWIRE) -- SiriusPoint Ltd. (“SiriusPoint” or the “Company”) (NYSE:SPNT) today announced results for its second quarter ended June 30, 2025 Combined ratio of 89.5% in the second quarter for Core business, representing a 3.8 point improvement from prior year and resulting in a half year Core combined ratio of 92.4%Underwriting income growth of 83% year over year in the second quarter to $68 million for Core businessStrong gross premiums written growth ...
SiriusPoint Announces Dividend on Series B Preference Shares
SiriusPoint Announces Dividend on Series B Preference Shares HAMILTON, Bermuda, Aug. 04, 2025 (GLOBE NEWSWIRE) -- SiriusPoint Ltd. (“SiriusPoint” or the “Company”) (NYSE: SPNT), an international specialty insurer and reinsurer, has announced that the Audit Committee of the Board of Directors of SiriusPoint Ltd. approved a quarterly cash dividend of $0.50 per share on its 8.00% Resettable Fixed Rate Preference Shares, Series B, $0.10 par value, $25.00 liquidation preference per share payable on or prior to August 29, 2025 to Series B shareholders of record as of August 14, 2025. About Sir...
- Jonathan Moreland
MERC MERCER INTERNATIONAL INC.
CDXS CODEXIS
PETS PETMED EXPRESS INC.
CLRB CELLECTAR BIOSCIENCES
NHF NEXPOINT CREDIT STRATEGIES FUN
CZWI CITIZENS COMMUNITY BANCORP
LOOP LOOP INDUSTRIES
CHMG CHEMUNG FINANCIAL CORP.
FVCB FVCBANKCORP
FGBI FIRST GUARANTY BANCSHARES
GRX THE GABELLI HEALTHCARE & WELLNESSRX TRUST
CMTV COMMUNITY BANCORP INC. VT
DMAC DIAMEDICA THERAPEUTICS INC.
CRDF CARDIFF ONCOLOGY INC
IMRX IMMUNEERING CORP
NSPR INSPIREMD INC
BRCC BRC INC
LEXX LEXARIA BIOSCIENCE CORP
PMNT PERFECT MOMENT LTD.
DMA DESTRA MULTI ALTERNATIVE FUND
NYC NEW YORK CITY REIT
GF INC.
FGEN THE NEW GERMANY FUND
CCIF INC.
CVM FIBROGEN INC.
CARLYLE CREDIT INCOME FUND
CEL-SCI CORPORATION
- Jonathan Moreland
ANTM ANTHEM INC.
SSB SOUTH STATE CORPORATION
SNV SYNOVUS FINANCIAL CORP.
SIGI SELECTIVE INSURANCE GROUP INC.
SFNC SIMMONS FIRST NATIONAL CORPORATION CLASS A
RLI RLI CORP.
PSX PHILLIPS 66
PRGS PROGRESS SOFTWARE CORPORATION
PNFP PINNACLE FINANCIAL PARTNERS INC.
NVCR NOVOCURE LTD.
MTH MERITAGE HOMES CORPORATION
MSCI MSCI INC. CLASS A
MOFG MIDWESTONE FINANCIAL GROUP
FBIZ FIRST BUSINESS FINANCIAL SERVICES
CNC CENTENE CORPORATION
CHTR CHARTER COMMUNICATIONS INC. CLASS A
ALGN ALIGN TECHNOLOGY INC.
UPS UNITED PARCEL SERVICE INC. CLASS B
PETS PETMED EXPRESS INC.
EPD ENTERPRISE PRODUCTS PARTNERS L.P.
PBT PERMIAN BASIN ROYALTY TRUST
LIND LINDBLAD EXPEDITIONS HOLDINGS
KYN KAYNE ANDERSON MLP INVESTMENT CO.
PLBC PLUMAS BANCORP
CZWI CITIZENS COMMUNITY BANCORP
MBIN MERCHANTS BANCORP
PGC PEAPACK-GLADSTONE FINANCIAL CORP.
LOOP LOOP INDUSTRIES
CHMG CHEMUNG FINANCIAL CORP.
FVCB FVCBANKCORP
TLRY TILRAY
TROX TRONOX HOLDINGS PLC
AMTB AMERANT BANCORP (A)
PCB PACIFIC CITY FINANCIAL CORP
DMAC DIAMEDICA THERAPEUTICS INC.
CRDF CARDIFF ONCOLOGY INC
ABSI ABSCI CORP
NSPR INSPIREMD INC
BRCC BRC INC
JMSB JOHN MARSHALL BANCORP INC
PRME PRIME MEDICINE INC
MMC MARSH & MCLENNAN COMPANIES INC.
STRW STRAWBERRY FIELDS REIT INC.
AURX NUO THERAPEUTICS
DMA INC.
MRAI DESTRA MULTI ALTERNATIVE FUND
GF MARPAI
CVM INC.
THE NEW GERMANY FUND
INC.
CEL-SCI CORPORATION
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.